Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Maurie Markman
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Disorders
Chemicals & Drugs
Procedures
Concepts & Ideas
Occupations
Sign-in to see full Profile
Network (preview)
46
Belinson, Jerome
43
Hoskins, William
39
Kulp, Barbara
35
Peterson, Gertrude
29
Almadrones, Lois
29
Webster, Kenneth
24
Zanotti, Kristine
23
Barakat, Richard
19
Curtin, J
16
Kennedy, A
12
Alberts, David
9
Liu, Ping-Yu
8
Saigo, Patricia
7
Rose, Peter
7
Wilczynski, Sharon
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Maurie Markman (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Markman Maurie
"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma" Safra T, et al (Gynecol Oncol 2009; 114:215-218).
Gynecologic oncology 2009;115(3):514; author reply 514-5.
-
2009: Tsimberidou Apostolia Maria; Vaklavas Christos; Wen Sijin; Hong David; Wheler Jennifer; Ng Chaan; Naing Aung; Tse Susan; Busaidy Naifa; Markman Maurie; Sherman Steven I; Kurzrock Razelle
Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.
The Journal of clinical endocrinology and metabolism 2009;94(11):4423-32.
-
2009: Markman Maurie
Comparative effectiveness research: a proposal for funding in ovarian cancer.
Gynecologic oncology 2009;115(2):182-3.
-
2009: Markman M
PET/CT scans in ovarian cancer: prognostic versus predictive utility?
Minerva medica 2009;100(5):415-20.
-
2009: Hennessy Bryan T; Coleman Robert L; Markman Maurie
Ovarian cancer.
Lancet 2009;374(9698):1371-82.
-
2009: Markman Maurie
Chemotherapy: Topotecan or treosulfan--that is the question.
Nature reviews. Clinical oncology 2009;6(10):559-60.
-
2009: Markman Maurie
Antiangiogenic drugs in ovarian cancer.
Expert opinion on pharmacotherapy 2009;10(14):2269-77.
-
2009: Markman Maurie
The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.
Gynecologic oncology 2009;114(3):536; author reply 536-7.
-
2009: Smith Harriet O; Moon James; Wilczynski Sharon P; Tiersten Amy D; Hannigan Edward V; Robinson William R; Rivkin Saul E; Anderson Garnet L; Liu P Y; Markman Maurie
Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.
Gynecologic oncology 2009;114(2):206-9.
-
2009: Markman Maurie; Liu P Y; Moon James; Monk Bradley J; Copeland Larry; Wilczynski Sharon; Alberts David
Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.
Gynecologic oncology 2009;114(2):195-8.
-
2009: Markman Maurie
A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.
Gynecologic oncology 2009;114(1):136-7; authore reply 137.
-
2009: Markman Maurie
Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites.
Journal of women's health (2002) 2009;18(6):827-9.
-
2009: Tian Chunqiao; Markman Maurie; Zaino Richard; Ozols Robert F; McGuire William P; Muggia Franco M; Rose Peter G; Spriggs David; Armstrong Deborah K
CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.
Cancer 2009;115(7):1395-403.
-
2009: Markman Maurie
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.
Gynecologic oncology 2009;113(1):4-5.
-
2009: Markman Maurie
An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.
Cancer journal (Sudbury, Mass.) 2009;15(2):105-9.
-
2009: Zorn Kristin K; Tian Chunqiao; McGuire William P; Hoskins William J; Markman Maurie; Muggia Franco M; Rose Peter G; Ozols Robert F; Spriggs David; Armstrong Deborah K
The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.
Cancer 2009;115(5):1028-35.
-
2009: Tiersten Amy D; Liu P Y; Smith Harriet O; Wilczynski Sharon P; Robinson William R; Markman Maurie; Alberts David S
Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Gynecologic oncology 2009;112(3):444-9.
-
2009: Markman Maurie
Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.
Therapeutics and clinical risk management 2009;5(1):161-8.
-
2009: Micha John P; Goldstein Bram H; Rettenmaier Mark A; Brown John V; John Cameron R; Markman Maurie
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):239-41.
-
2009: Markman Maurie; Brady Mark; Hutson Alan; Berek Jonathan S
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009;19(2):223-9.
-
2009: Winer Eric; Gralow Julie; Diller Lisa; Karlan Beth; Loehrer Patrick; Pierce Lori; Demetri George; Ganz Patricia; Kramer Barnett; Kris Mark; Markman Maurie; Mayer Robert; Pfister David; Raghavan Derek; Ramsey Scott; Reaman Gregory; Sandler Howard; Sawaya Raymond; Schuchter Lynn; Sweetenham John; Vahdat Linda; Schilsky Richard L;
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(5):812-26.
-
2009: Markman Maurie
The myth of measurable disease in ovarian cancer: revisited.
Cancer investigation 2009;27(1):11-2.
-
2009: Cox James D; Giralt Sergio A; Veazie Mary L; Ajani Jaffer A; Bruner Janet M; Chan Ka Wah; Hittelman Walter N; Hunt Kelly K; Iyer Revathy B; Karp Daniel D; Kuban Deborah A; Lippman Scott M; Raad Issam I; Rodriguez-Bigas Miguel A; Zwelling Leonard A; Markman Maurie
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.
Oncology 2009;77(2):75-81.
-
2009: Markman Maurie
Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents.
Oncology 2009;76(4):229-30.
-
2009: Markman Maurie
Therapeutic intent in the conduct of phase I antineoplastic drug trials.
Oncology 2009;76(3):149-50.
-
2008: Markman Maurie
Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.
Current oncology reports 2008;10(6):447-8.
-
2008: Markman Maurie
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Cancer 2008;113(10):2832-3; author reply 2833-4.
-
2008: Markman Maurie
Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
Trends in pharmacological sciences 2008;29(10):515-9.
-
2008: Markman Maurie
The remarkable "paclitaxel story": how many chapters remain to be written?
Gynecologic oncology 2008;111(1):7-8.
-
2008: Markman Maurie
Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies.
Current oncology reports 2008;10(5):359-60.
-
2008: Markman Maurie
Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.
Gynecologic oncology 2008;110(3):275-7.
-
2008: Markman Maurie
Assigning a cause for a particular outcome in oncology: a serious note of caution.
Cancer 2008;113(4):668-70.
-
2008: Markman Maurie
Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences.
Current oncology reports 2008;10(4):271-2.
-
2008: Orr James; Kelley Joseph; Dizon Don; Escobar Pedro; Fleming Evelyn; Gemignani Mary; Hetzel David; Hoskins William; Kieback Dirk; Kilgore Larry; LaPolla James; Lewin Sharyn; Lucci Joseph; Markman Maurie; Pothuri Bhavana; Powell C Bethan; Tejada-Berges Trevor
Society of gynecologic oncologists position paper: breast cancer care.
Gynecologic oncology 2008;110(1):7-12.
-
2008: Markman Maurie
Second-line therapy for ovarian cancer.
Clinical advances in hematology & oncology : H&O 2008;6(6):421-2.
-
2008: Markman Maurie
Benefits of religious beliefs for cancer patients: a response to Dawkins and Hitchens.
Current oncology reports 2008;10(3):185-7.
-
2008: Markman Maurie
An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development.
Cancer 2008;112(9):1871-3.
-
2008: Alberts David S; Marth Christian; Alvarez Ronald D; Johnson Gary; Bidzinski Mariusz; Kardatzke David R; Bradford Williamson Z; Loutit Jeff; Kirn David H; Clouser Mary C; Markman Maurie;
Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Gynecologic oncology 2008;109(2):174-81.
-
2008: Fader Amanda Nickles; von Gruenigen Vivian; Gibbons Heidi; Abushahin Fadi; Starks David; Markman Maurie; Belinson Jerome; Rose Peter
Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients.
Gynecologic oncology 2008;109(1):33-8.
-
2008: Markman Maurie
Evidence-based chemotherapy administration in advanced ovarian cancer: an impressive past, a disquieting present and an uncertain future.
Gynecologic oncology 2008;109(1):4-7.
-
2008: Markman Maurie
Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?
Current oncology reports 2008;10(2):93-4.
-
2008: Markman M
Maintenance chemotherapy in advanced ovarian cancer: the US experience.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():40-3.
-
2008: Markman M
What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():36-9.
-
2008: Markman M
Strategies to examine new compounds for intraperitoneal use in ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2008;18 Suppl 1():33-5.
-
2008: Markman Maurie
"Conflict-of-interest" and participation in IRB deliberations: an alternative perspective.
Cancer investigation 2008;26(2):115-7.
-
2008: Markman Maurie
Re: "Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials".
Gynecologic oncology 2008;108(3):658; author reply 658-9.
-
2008: Markman Maurie
Critical thinking: an essential role in both the conduct and interpretation of gynecologic cancer clinical research.
Gynecologic oncology 2008;108(3):462-5.
-
2008: Markman Maurie
Taxanes in the management of gynecologic malignancies.
Expert review of anticancer therapy 2008;8(2):219-26.
-
2008: Markman Maurie
Objective data rather than opinion in the interpretation of the legitimate goals of phase 1 oncology trials.
Cancer investigation 2008;26(1):11-2.
-
2008: Markman Maurie
Prohibition against competing cancer clinical trials: a counter argument.
Cancer 2008;112(3):455-7.
-
2008: Markman Maurie
The increasingly complex world of cancer patient advocacy organizations.
Current oncology reports 2008;10(1):1-2.
-
2008: Gralow Julie; Ozols Robert F; Bajorin Dean F; Cheson Bruce D; Sandler Howard M; Winer Eric P; Bonner James; Demetri George D; Curran Walter; Ganz Patricia A; Kramer Barnett S; Kris Mark G; Markman Maurie; Mayer Robert J; Raghavan Derek; Ramsey Scott; Reaman Gregory H; Sawaya Raymond; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Davidson Nancy E; Schilsky Richard L; Lichter Allen S;
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(2):313-25.
-
2008: Alberts David S; Liu P Y; Wilczynski Sharon P; Clouser Mary C; Lopez Ana Maria; Michelin David P; Lanzotti Victor J; Markman Maurie;
Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200).
Gynecologic oncology 2008;108(1):90-4.
-
2008: Markman Maurie; Petersen Judy; Montgomery Robert
An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials.
Journal of cancer research and clinical oncology 2008;134(1):115-8.
-
2008: Markman Maurie
The promise and perils of 'targeted therapy' of advanced ovarian cancer.
Oncology 2008;74(1-2):1-6.
-
2008: Markman Maurie
Pharmaceutical management of ovarian cancer : current status.
Drugs 2008;68(6):771-89.
-
2007: Markman Maurie
"Of models and men (or women)"--a brief story of a mathematical model and its influence on the management of ovarian cancer.
Cancer investigation 2007;25(8):666-7.
-
2007: Markman Jonathan R; Markman Maurie
Running an ethical trial 60 years after the Nuremberg Code.
The lancet oncology 2007;8(12):1139-46.
-
2007: Markman Maurie
The role of independent review to insure ethical quality-improvement activities in oncology: a commentary on the national debate regarding the distinction between quality-improvement initiatives and clinical research.
Cancer 2007;110(12):2597-600.
-
2007: Markman Maurie
HPV vaccination and the prevention of cervical cancer: the long road ahead.
Journal of women's health (2002) 2007;16(9):1366-7.
-
2007: Markman Maurie
Diagnostic dilemmas in cancer medicine: focusing on the treatable.
Current oncology reports 2007;9(6):429-30.
-
2007: Markman Maurie
The CA125 antigen level as a prognostic versus a predictive test in epithelial ovarian cancer.
Nature clinical practice. Oncology 2007;4(11):628-9.
-
2007: Markman Maurie
The dilemma of carboplatin-associated hypersensitivity reactions in ovarian cancer management.
Gynecologic oncology 2007;107(2):163-5.
-
2007: Atallah Ehab; Cortes Jorge; O'Brien Susan; Pierce Sherry; Rios Mary Beth; Estey Elihu; Markman Maurie; Keating Michael; Freireich Emil J; Kantarjian Hagop
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia.
Blood 2007;110(10):3547-51.
-
2007: Markman Maurie
Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution.
Cancer 2007;110(8):1644-7.
-
2007: Markman Maurie
Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions.
Reviews on recent clinical trials 2007;2(3):169-73.
-
2007: Markman Maurie
Concept of optimal surgical cytoreduction in advanced ovarian cancer: a brief critique and a call for action.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(27):4168-70.
-
2007: Markman Maurie
Recognizing the toxicity of "nontoxic" drugs employed in the management of malignant disease.
Current oncology reports 2007;9(5):329-30.
-
2007: Winter William E; Maxwell G Larry; Tian Chunqiao; Carlson Jay W; Ozols Robert F; Rose Peter G; Markman Maurie; Armstrong Deborah K; Muggia Franco; McGuire William P;
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3621-7.
-
2007: Liu Ping-Yu; Alberts David S; Monk Bradley J; Brady Mark; Moon James; Markman Maurie
An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(24):3615-20.
-
2007: Markman Maurie
Does ovarian cancer treatment and survival differ by the specialty providing chemotherapy?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3554; author reply 3557-8.
-
2007: Markman Maurie
Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials.
Gynecologic oncology 2007;106(2):279-81.
-
2007: Markman Maurie
Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
Gynecologic oncology 2007;106(2):433.
-
2007: Markman Maurie
Mentoring in the ethics of clinical research: an ongoing need.
Current oncology reports 2007;9(4):235-6.
-
2007: Markman Maurie
Development of an ovarian cancer symptom index: possibilities for earlier detection.
Cancer 2007;110(1):226; author reply 227.
-
2007: Markman Maurie
Platinum-based neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecologic oncology 2007;106(1):273-4; author reply 274-5.
-
2007: Alberts D S; Liu P Y; Wilczynski S P; Jang A; Moon J; Ward J H; Beck J T; Clouser M; Markman M
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2007;17(4):784-8.
-
2007: Markman Maurie
Human papillomavirus vaccines to prevent cervical cancer.
Lancet 2007;369(9576):1837-9.
-
2007: Freedman Ralph S; Markman Maurie
Food and drug administration expanded access to treatment: implications for oncology patients.
Cancer 2007;109(11):2157-60.
-
2007: Markman Maurie
A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.
Gynecologic oncology 2007;105(3):561-2.
-
2007: Markman Maurie
Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.
Current oncology reports 2007;9(3):159-60.
-
2007: Markman Maurie
The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature.
Cancer 2007;109(10):1929-32.
-
2007: Bukowski Ronald M; Ozols Robert F; Markman Maurie
The management of recurrent ovarian cancer.
Seminars in oncology 2007;34(2 Suppl 2):S1-15.
-
2007: Markman Maurie
Effect of obesity on survival in epithelial ovarian cancer.
Cancer 2007;109(7):1446; author reply 1447.
-
2007: Markman Maurie
Re: "Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study".
Gynecologic oncology 2007;105(1):279-80; author reply 280-1.
-
2007: Markman Maurie
Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology.
Cancer 2007;109(6):1003-6.
-
2007: Markman Maurie
Care of the incarcerated cancer patient.
Current oncology reports 2007;9(2):81-2.
-
2007: Markman Maurie
Re: "En bloc resection of diaphragm with lung for recurrent ovarian cancer: a case report".
Gynecologic oncology 2007;104(3):781; author reply 781-2.
-
2007: Markman Maurie
New, expanded, and modified use of approved antineoplastic agents in ovarian cancer.
The oncologist 2007;12(2):186-90.
-
2007: Homesley Howard D; Filiaci Virginia; Markman Maurie; Bitterman Pincas; Eaton Lynne; Kilgore Larry C; Monk Bradley J; Ueland Frederick R;
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):526-31.
-
2007: Markman Maurie
The objectivity of reports describing the use of novel diagnostic tests in the management of ovarian cancer: a critique.
Gynecologic oncology 2007;104(2):271-2.
-
2007: Markman Maurie
Cancer screening: understanding barriers to optimal use of evidence-based strategies.
Journal of women's health (2002) 2007;16(1):9-10.
-
2007: Markman Maurie; Smoyer Larie; Marron J Timothy; Montgomery Robert
Cancer versus heart failure patient self-declared potential interest in clinical trials.
Current oncology reports 2007;9(1):1-5.
-
2007: Ozols Robert F; Herbst Roy S; Colson Yolonda L; Gralow Julie; Bonner James; Curran Walter J; Eisenberg Burton L; Ganz Patricia A; Kramer Barnett S; Kris Mark G; Markman Maurie; Mayer Robert J; Raghavan Derek; Reaman Gregory H; Sawaya Raymond; Schilsky Richard L; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Winn Rodger J;
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):146-62.
-
2007: Rose Peter G; Greer Benjamin E; Horowitz Ira R; Markman Maurie; Fusco Nancy
Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Gynecologic oncology 2007;104(1):114-9.
-
2007: Markman Maurie
Comorbidity as a focus of clinical cancer trials: an important unmet need.
Oncology 2007;73(5-6):279-80.
-
2007: Markman Maurie
Development of an effective breast and cervix cancer screening strategy in Mumbai: an impressive effort.
Oncology 2007;73(3-4):143-4.
-
2007: Markman Maurie
Reducing the worldwide burden of cancer.
Oncology 2007;73(1-2):1.
-
2007: Markman Maurie
The rapidly changing oncology landscape: a time for transition in oncology.
Oncology 2007;72(5-6):417-8.
-
2007: Markman Maurie
Are we entering the era of maintenance therapy of advanced malignant disease?
Oncology 2007;72(5-6):265-6.
-
2007: Markman Maurie
A need to document a role for palliative chemotherapy in the management of progressive malignant disease.
Oncology 2007;72(3-4):162-3.
-
2007: Markman Maurie
Use of systemic antineoplastic drug therapy after regulatory agency approval.
Oncology 2007;72(3-4):145-6.
-
2007: Markman Maurie
Increasing entry of the elderly into cancer clinical trials: difficult, but unquestionably necessary.
Oncology 2007;72(1-2):2-3.
-
2007: Markman Maurie
Justification for separate consideration of two broad categories of cancer patient use of complementary medicine.
Journal of the Society for Integrative Oncology 2007;5(2):50-2.
-
2007: Markman Maurie
Intraperitoneal chemotherapy in the management of ovarian cancer.
Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer 2007;169():165-76.
-
2006: Markman Maurie
Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer.
Seminars in oncology 2006;33(6 Suppl 12):S3-7.
-
2006: Alberts D S; Markman M; Muggia F; Ozols R F; Eldermire E; Bookman M A; Chen T; Curtin J; Hess L M; Liebes L; Young R C; Trimble E
Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer.
Gynecologic oncology 2006;103(3):783-92.
-
2006: Markman Maurie
Hormonal therapy for epithelial ovarian cancer.
Women's health (London, England) 2006;2(6):847-51.
-
2006: Markman Maurie
The role of intraperitoneal chemotherapy in ovarian cancer.
Clinical advances in hematology & oncology : H&O 2006;4(11):809-10.
-
2006: Markman Maurie
Evaluation of the clinical utility of diagnostic versus therapeutic interventions in oncology: related but quite different processes.
Current oncology reports 2006;8(6):407-8.
-
2006: Navo Marisa; Kunthur Anuradha; Badell Martina L; Coffer Larry W; Markman Maurie; Brown Jubilee; Smith Judith A
Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients.
Gynecologic oncology 2006;103(2):608-13.
-
2006: Armstrong Deborah K; Fleming Gini F; Markman Maurie; Bailey Howard H
A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;103(2):391-6.
-
2006: Markman Maurie; Federico Massimo; Liu P Y; Hannigan Edward; Alberts David
Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer.
Gynecologic oncology 2006;103(1):195-8.
-
2006: Tso Elisa; Elson Paul; Vanlente Fred; Markman Maurie
The "real-life" variability of CA-125 in ovarian cancer patients.
Gynecologic oncology 2006;103(1):141-4.
-
2006: Markman Maurie
The "new" era of oral antineoplastic drug therapy: revisiting "old" concerns.
Current oncology reports 2006;8(5):317-8.
-
2006: Markman Maurie
Descriptions in the peer-reviewed literature of the results of phase 2 chemotherapy trials involving gynecologic malignancies: a call for greater objectivity.
Gynecologic oncology 2006;102(3):419-20.
-
2006: Markman Maurie
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary.
Expert opinion on pharmacotherapy 2006;7(11):1469-74.
-
2006: Markman Maurie
Chemotherapy-induced peripheral neuropathy: underreported and underappreciated.
Current pain and headache reports 2006;10(4):275-8.
-
2006: Markman Maurie; Petersen Judith; Montgomery Robert
Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials.
Cancer 2006;107(4):849-53.
-
2006: Herzog Thomas J; Coleman Robert L; Markman Maurie; Cella David; Thigpen J Tate
The role of maintenance therapy and novel taxanes in ovarian cancer.
Gynecologic oncology 2006;102(2):218-25.
-
2006: Rose Peter G; Markman Maurie; Bell Jeffrey G; Fusco Nancy L
Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study.
Gynecologic oncology 2006;102(2):236-9.
-
2006: Markman Maurie
The diagnostic "gold standard" in oncology: increasing importance and increasing concerns.
Current oncology reports 2006;8(4):237-8.
-
2006: Markman Maurie
"Therapeutic intent" in phase 1 oncology trials: a justifiable objective.
Archives of internal medicine 2006;166(14):1446-8.
-
2006: Markman Maurie
Normal CA-125 and the risk of progression in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(20):3310; author reply 3310-1.
-
2006: Markman Maurie; Markman Margaret; Petersen Judith; Belland Angela
Clinical features of American versus non-American gynecologic cancer patients requesting information from a proprietary web-based decision-support program.
Journal of cancer research and clinical oncology 2006;132(7):439-43.
-
2006: Markman Maurie
Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Gynecologic oncology 2006;101(3):550-1; author reply 551-2.
-
2006: Markman Maurie; Blessing John; Rubin Stephen C; Connor Joseph; Hanjani Parviz; Waggoner Steven
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study.
Gynecologic oncology 2006;101(3):436-40.
-
2006: Markman Maurie
Quality assurance in oncology.
Current oncology reports 2006;8(3):155-56.
-
2006: Micha J P; Goldstein B H; Rettenmaier M A; Brown J V; John C R; Markman M
Surgery alone or surgery with a combination radiation or chemoradiation for management of patients with bulky-stage IB2 cervical carcinoma.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(3):1147-51.
-
2006: Markman Maurie
Palliative chemotherapy "near the end-of-life" in ovarian cancer: not necessarily "aggressive cure-oriented therapy".
Gynecologic oncology 2006;101(2):198-9.
-
2006: Markman Maurie
Unresolved issues in the chemotherapeutic management of gynecologic malignancies.
Seminars in oncology 2006;33(2 Suppl 6):S33-8.
-
2006: Markman Maurie
Management of ovarian cancer. An impressive history of improvement in survival and quality of life.
Oncology (Williston Park, N.Y.) 2006;20(4):347-54; discussion 354, 357-8, 364 passim.
-
2006: Markman Maurie; Markman Margaret R; Belland Angela; Petersen Judith
Profile of ovarian cancer patients seeking information from a web-based decision support program.
Journal of women's health (2002) 2006;15(3):312-8.
-
2006: Markman Maurie
Providing research participants with findings from completed cancer-related clinical trials: not quite as simple as it sounds.
Cancer 2006;106(7):1421-4.
-
2006: Markman Maurie; Liu P Y; Rothenberg Mace L; Monk Bradley J; Brady Mark; Alberts David S
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(9):1454-8.
-
2006: Markman Maurie
Cancer survivorship: the concept and the increasingly recognized reality.
Current oncology reports 2006;8(2):79-80.
-
2006: Thall Peter F; Estey Elihu H; Markman Maurie
Some ethical issues in phase II trials in acute leukemia.
Clinical advances in hematology & oncology : H&O 2006;4(2):95.
-
2006: Markman Maurie
Another example of the highly variable clinical course of recurrent/resistant/persistent ovarian cancer.
Cancer investigation 2006;24(1):109.
-
2006: Markman Maurie; Walker Joan L
Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):988-94.
-
2006: Markman Maurie
Re: "Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival".
Gynecologic oncology 2006;100(2):443; author reply 444.
-
2006: Markman Maurie
Viewing ovarian cancer as a "chronic disease": what exactly does this mean?
Gynecologic oncology 2006;100(2):229-30.
-
2006: Markman Maurie
Turning cervix cancer into a "rare disease": is society prepared to do what is required to make this a reality?
Current oncology reports 2006;8(1):1-2.
-
2006: Smith H O; Jiang C S; Weiss G R; Hallum A V; Liu P Y; Robinson W R; Cheng P C; Scudder S A; Markman M; Alberts D S
Tirapazamine plus cisplatin in advanced or recurrent carcinoma of the uterine cervix: a Southwest Oncology Group study.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2006;16(1):298-305.
-
2006: Herbst Roy S; Bajorin Dean F; Bleiberg Harry; Blum Diane; Hao Desirée; Johnson Bruce E; Ozols Robert F; Demetri George D; Ganz Patricia A; Kris Mark G; Levin Bernard; Markman Maurie; Raghavan Derek; Reaman Gregory H; Sawaya Raymond; Schuchter Lynn M; Sweetenham John W; Vahdat Linda T; Vokes Everett E; Winn Rodger J; Mayer Robert J;
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):190-205.
-
2006: Markman Maurie
Assuring the ethical conduct of clinical cancer trials in the developing world.
Cancer 2006;106(1):1-3.
-
2006: Alberts David S; Hannigan Edward V; Liu Ping-Yu; Jiang Caroline; Wilczynski Sharon; Copeland Larry; Markman Maurie
Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: An intergroup study.
Gynecologic oncology 2006;100(1):133-8.
-
2006: Markman Maurie
Optimizing management of recurrent epithelial ovarian cancer: a critical need for evidence-based data.
Oncology 2006;71(5-6):309-11.
-
2006: Markman Maurie
Efforts to define a role for recombinant erythropoietin in cancer management.
Oncology 2006;71(3-4):149-50.
-
2006: Micha John P; Goldstein Bram H; Graham Cheri; Rettenmaier Mark A; Brown John V; Hu Jim C; Markman Maurie
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Oncology 2006;71(1-2):49-53.
-
2006: Markman Maurie
Presentations of phase 2 clinical trial abstracts at a national oncology meeting: potential implications for subsequent publication in the peer-reviewed literature.
Oncology 2006;71(1-2):146-7.
-
2005: Straughn J Michael; Numnum T Michael; Kilgore Larry C; Partridge Edward E; Phillips Jerri Linn; Markman Maurie; Thomas Gillian M; Burke Thomas W;
The use of adjuvant radiation therapy in patients with intermediate-risk Stages IC and II uterine corpus cancer: a patient care evaluation study from the American College of Surgeons National Cancer Data Base.
Gynecologic oncology 2005;99(3):530-5.
-
2005: Markman Maurie
Fever of unknown origin and cancer: a clinically meaningful association.
The lancet oncology 2005;6(11):821-2.
-
2005: Markman Maurie
A "snapshot" of an ovarian cancer clinical practice: evidence for viewing the malignancy as a "chronic disease".
Current oncology reports 2005;7(6):393-4.
-
2005: Markman Maurie
Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity.
The oncologist 2005;10(9):695-7.
-
2005: Markman Maurie
Chemosensitivity and chemoresistance testing.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(29):7363-4.
-
2005: Markman Maurie
Use of positron emission tomography scans in ovarian cancer: a diagnostic technique in search of an indication.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7385-7.
-
2005: Markman Timothy M; Markman Maurie
The patient and Web-based cancer information: a role for provider input into this rapidly evolving relationship.
Current oncology reports 2005;7(5):313-4.
-
2005: Uyar Denise; Frasure Heidi E; Markman Maurie; von Gruenigen Vivian E
Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer.
Gynecologic oncology 2005;98(3):403-8.
-
2005: Michener Chad M; Peterson Gertrude; Kulp Barbara; Webster Kenneth D; Markman Maurie
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Journal of cancer research and clinical oncology 2005;131(9):581-4.
-
2005: Markman Maurie
Unique issues in the development of "targeted" antineoplastic pharmaceutical agents.
Current oncology reports 2005;7(4):235-6.
-
2005: Kim Robert J; Peterson Gertrude; Kulp Barbara; Zanotti Kristine M; Markman Maurie
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Gynecologic oncology 2005;97(2):374-8.
-
2005: Markman Maurie
Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists.
Current oncology reports 2005;7(3):159-60.
-
2005: Fujiwara Keiichi; Markman Maurie; Morgan Mark; Coleman Robert L
Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer.
Gynecologic oncology 2005;97(1):10-5.
-
2005: Markman Maurie
Hormonal therapy of endometrial cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(5):673-5.
-
2005: Scudder Sidney A; Liu P Y; Wilczynski Sharon P; Smith Harriet O; Jiang Caroline; Hallum Alton V; Smith Gregory B; Hannigan Edward V; Markman Maurie; Alberts David S;
Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group.
Gynecologic oncology 2005;96(3):610-5.
-
2005: Markman Maurie
Care of pediatric cancers in the developing world: should this be a societal priority?
Current oncology reports 2005;7(2):81-2.
-
2005: Markman Maurie
'Flat-fixed dosing' of chemotherapy: a concept whose time has come?
Current oncology reports 2005;7(1):1-2.
-
2005: Micha John P; Goldstein Bram H; Mattison Julie A; Bader Kathy; Graham Cheri; Rettenmaier Mark A; Brown John V; Markman Maurie
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Gynecologic oncology 2005;96(1):132-5.
-
2005: Thigpen J Tate; Aghajanian Carol A; Alberts David S; Campos Susana M; Gordon Alan N; Markman Maurie; McMeekin D Scott; Monk Bradley J; Rose Peter G
Role of pegylated liposomal doxorubicin in ovarian cancer.
Gynecologic oncology 2005;96(1):10-8.
-
2005: Markman Maurie; Belinson Jerome
A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers.
Journal of cancer research and clinical oncology 2005;131(1):26-30.
-
2005: Markman Maurie
Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice.
Cancer investigation 2005;23(8):735-40.
-
2005: Markman Maurie; Petersen Judith; Montgomery Robert
An examination of characteristics of lung and colon cancer patients participating in a web-based decision support program. Internet-based decision support programs.
Oncology 2005;69(4):311-6.
-
2005: Markman Maurie
Supportive care.
Cancer chemotherapy and biological response modifiers 2005;22():677-86.
-
2005: Markman Maurie; Webster Kenneth; Kulp Barbara; Peterson Gertrude
Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications.
Cancer investigation 2005;23(1):33-5.
-
2004: Markman Maurie; Gordon Alan N; McGuire William P; Muggia Franco M
Liposomal anthracycline treatment for ovarian cancer.
Seminars in oncology 2004;31(6 Suppl 13):91-105.
-
2004: Rothenberg Mace L; Liu P Y; Wilczynski Sharon; Nahhas William A; Winakur Gaye L; Jiang Caroline S; Moinpour Carol M; Lyons Ben; Weiss Geoffrey R; Essell James H; Smith Harriet O; Markman Maurie; Alberts David S
Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
Gynecologic oncology 2004;95(3):506-12.
-
2004: Markman Maurie; Markman Jon; Webster Kenneth; Zanotti Kristine; Kulp Barbara; Peterson Gertrude; Belinson Jerome
Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
Journal of cancer research and clinical oncology 2004;130(12):741-4.
-
2004: Markman Maurie
Point: Intraperitoneal chemotherapy in the management of ovarian cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2004;2(6):549-54.
-
2004: Markman Maurie
Recent reminders of why the gold standard for clinical research in oncology is the well-designed and conducted randomized phase III trial.
Current oncology reports 2004;6(6):421-2.
-
2004: Markman Maurie
Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
Journal of cancer research and clinical oncology 2004;130(11):645-8.
-
2004: Lavey Robert S; Liu P Y; Greer Benjamin E; Robinson William R; Chang Pui C; Wynn Raymond B; Conrad Marcel E; Jiang Caroline; Markman Maurie; Alberts David S
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study.
Gynecologic oncology 2004;95(1):145-51.
-
2004: Markman Maurie; Webster Kenneth; Zanotti Kristine; Kulp Barbara; Peterson Gertrude; Belinson Jerome
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology 2004;95(1):109-13.
-
2004: Markman Maurie
What is the clinically relevant endpoint for cancer prevention trials?
Current oncology reports 2004;6(5):329-30.
-
2004: Markman Maurie; Kulp Barbara; Peterson Gertrude
Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Gynecologic oncology 2004;94(2):578-80.
-
2004: Markman Maurie; Webster Kenneth; Zanotti Kristine; Peterson Gertrude; Kulp Barbara; Belinson Jerome
Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Gynecologic oncology 2004;94(2):404-8.
-
2004: Markman Maurie; Markman Jonathan; Webster Kenneth; Zanotti Kristine; Kulp Barbara; Peterson Gertrude; Belinson Jerome
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3120-5.
-
2004: Markman Maurie
Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103.
Journal of experimental therapeutics & oncology 2004;4(2):131-6.
-
2004: Uyar Denise; Kulp Barbara; Peterson Gertrude; Zanotti Kristine; Markman Maurie; Belinson Jerome
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Gynecologic oncology 2004;94(1):147-51.
-
2004: Markman Maurie
Translating the results of phase III randomized cancer trials into the language of physician obligation to patients.
Current oncology reports 2004;6(4):243-4.
-
2004: Markman Maurie
Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management.
Journal of cancer research and clinical oncology 2004;130(7):383-7.
-
2004: Markman Maurie; Webster Kenneth; Zanotti Kristine; Peterson Gertrude; Kulp Barbara; Belinson Jerome
Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.
Gynecologic oncology 2004;93(3):715-7.
-
2004: Markman Maurie; Webster Kenneth; Zanotti Kristine; Peterson Gertrude; Kulp Barbara; Belinson Jerome
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Gynecologic oncology 2004;93(3):699-701.
-
2004: Markman Maurie
What must research subjects be told regarding the results of completed randomized trials?
IRB 2004;26(3):8-10.
-
2004: Markman Maurie; Webster Kenneth; Zanotti Kristine; Rohl Jacqueline; Belinson Jerome
Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer.
Gynecologic oncology 2004;93(2):390-3.
-
2004: Markman Maurie
Intraperitoneal hyperthermic chemotherapy as treatment of peritoneal carcinomatosis of colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1527; author reply 1529.
-
2004: Alberts D S; Jiang C; Liu P Y; Wilczynski S; Markman M; Rothenberg M L
Long-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2004;14(2):224-8.
-
2004: Markman Maurie
Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?
Current oncology reports 2004;6(2):75-6.
-
2004: Markman Jonathan; Zanotti Kristine; Webster Kenneth; Belinson Jerome; Peterson Gertrude; Kulp Barbara; Markman Maurie
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 2004;92(2):592-5.
-
2004: Escobar Pedro F; Markman Maurie; Rose Peter; Zanotti Kristine; Webster Kenneth; Belinson Jerome
Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology 2004;92(1):192-6.
-
2004: Markman Maurie; Fowler Jeffrey
Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel.
Gynecologic oncology 2004;92(1):180-2.
-
2004: Markman Maurie
Genetic discrimination arising from cancer risk assessments: a societal dilemma.
Cleveland Clinic journal of medicine 2004;71(1):12, 15-8.
-
2004: Markman Maurie
Is it time for oncologists to modify their laissez-faire attitude toward alternative/complementary 'drug therapy'?
Current oncology reports 2004;6(1):1-2.
-
2004: Markman Maurie; Hsieh Fred; Zanotti Kristine; Webster Kenneth; Peterson Gertrude; Kulp Barbara; Spicel Ann; Belinson Jerome
Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Journal of cancer research and clinical oncology 2004;130(1):25-8.
-
2004: DeMarco Joseph P; Markman Maurie
The research misconception.
The International journal of applied philosophy 2004;18(2):241-52.
-
2004: Markman Maurie
Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
Cancer investigation 2004;22(3):471-3.
-
2004: Markman Maurie; Belinson Jerome; Webster Kenneth; Zanotti Kristine; Morrison Bei; Jacobs Barbara; Borden Ernest; Lindner Daniel
Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.
Oncology 2004;66(5):343-6.
-
2004: Markman Maurie
Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community.
The oncologist 2004;9(1):3-7.
-
2003: Markman Maurie
The needs of science vs the needs of patients: ethical concerns in cancer clinical trials.
Cleveland Clinic journal of medicine 2003;70(12):1008-9, 1013-4, 1016.
-
2003: Markman Maurie; Zanotti Kristine; Webster Kenneth; Peterson Gertrude; Kulp Barbara; Belinson Jerome
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Gynecologic oncology 2003;91(3):573-6.
-
2003: Markman Maurie; Zanotti Kristine; Peterson Gertrude; Kulp Barbara; Webster Kenneth; Belinson Jerome
Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4611-4.
-
2003: Markman Maurie
Prevention of paclitaxel-associated arthralgias and myalgias.
The journal of supportive oncology 2003;1(4):233-4.
-
2003: DeMarco Joseph P; Markman Maurie
Clinical equipoise: more uncertainty.
The Hastings Center report 2003;33(6):4; author reply 4-5.
-
2003: Markman M
Consolidation therapy revisited: intravenous chemotherapy.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2003;13 Suppl 2():204-7.
-
2003: Schwartz Benjamin M; Khuntia Deepak; Kennedy Alexander W; Markman Maurie
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
Gynecologic oncology 2003;91(2):421-2.
-
2003: Markman Maurie
Toxicities of the platinum antineoplastic agents.
Expert opinion on drug safety 2003;2(6):597-607.
-
2003: Markman Maurie
Consolidation/maintenance chemotherapy for ovarian cancer.
Current oncology reports 2003;5(6):454-8.
-
2003: Markman Maurie
Surgical staging of cancer: impact on prognosis and potential for bias in clinical trials.
Current oncology reports 2003;5(6):437-8.
-
2003: Escobar Pedro F; Markman Maurie; Zanotti Kristine; Webster Kenneth; Belinson Jerome
Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer.
Journal of cancer research and clinical oncology 2003;129(11):651-4.
-
2003: Uyar Denise; Takigawa Nagio; Mekhail Tarek; Grabowski Dale; Markman Maurie; Lee Francis; Canetta Renzo; Peck Ron; Bukowski Ronald; Ganapathi Ram
Apoptotic pathways of epothilone BMS 310705.
Gynecologic oncology 2003;91(1):173-8.
-
2003: Markman Maurie; Elson Paul; Kulp Barb; Peterson Gertrude; Zanotti Kristine; Webster Kenneth; Belinson Jerome
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.
Gynecologic oncology 2003;91(1):118-22.
-
2003: Markman Maurie; Webster Kenneth; Zanotti Kristine; Kulp Barbara; Peterson Gertrude; Belinson Jerome
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Gynecologic oncology 2003;90(3):593-6.
-
2003: Markman Maurie
Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies.
Cancer 2003;98(5):885-7.
-
2003: Markman Maurie
Randomized trials in oncology: a fertile ground for controversy.
Current oncology reports 2003;5(5):347-8.
-
2003: Markman Maurie
Optimizing primary chemotherapy in ovarian cancer.
Hematology/oncology clinics of North America 2003;17(4):957-68, viii.
-
2003: Markman Maurie
The myth of measurable disease in ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(16):3013-5.
-
2003: Markman Maurie
Are we winning or losing the war on cancer?
Cleveland Clinic journal of medicine 2003;70(7):632-3.
-
2003: Markman Maurie; DeMarco Joseph
Potential conflict between fundamental ethical principles and requirements of the oncology drug approval process: ethical conflict in drug approval.
Cancer 2003;98(2):215-8.
-
2003: Markman Maurie
Outcomes of two antiemetic therapies are the same.
Oncology nursing forum 2003;30(4):551-5; author reply 551-5.
-
2003: Markman Maurie; Liu P Y; Wilczynski Sharon; Monk Bradley; Copeland Larry J; Alvarez Ronald D; Jiang Caroline; Alberts David;
Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2460-5.
-
2003: Markman Maurie
Limitations to the use of the CA-125 antigen level in ovarian cancer.
Current oncology reports 2003;5(4):263-4.
-
2003: Markman Margaret; Zanotti Kristine; Kulp Barbara; Peterson Gertrude; Markman Maurie
Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Gynecologic oncology 2003;89(3):514-6.
-
2003: Covens Allan; Brunetto Virginia L; Markman Maurie; Orr James W; Lentz Samuel S; Benda Jo;
Phase II trial of danazol in advanced, recurrent, or persistent endometrial cancer: a Gynecologic Oncology Group study.
Gynecologic oncology 2003;89(3):470-4.
-
2003: Markman Maurie
Does palliative chemotherapy palliate?
The journal of supportive oncology 2003;1(1):65-7.
-
2003: Markman Maurie; Zanotti Kristine; Webster Kenneth; Belinson Jerome; Rose Peter
Toxicity associated with carboplatin/paclitaxel/Irinotecan use in advanced ovarian cancer: preliminary analysis.
Oncology (Williston Park, N.Y.) 2003;17(5 Suppl 5):34-5.
-
2003: Markman Maurie
Role of intraperitoneal chemotherapy in the front-line setting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):145s-148s.
-
2003: Cannistra Stephen A; Bast Robert C; Berek Jonathan S; Bookman Michael A; Crum Christopher P; DePriest Paul D; Garber Judy E; Koh Wui-Jin; Markman Maurie; McGuire William P; Rose Peter G; Rowinsky Eric K; Rustin Gordon J S; Skates Steven J; Vasey Paul A; King Laura
Progress in the management of gynecologic cancer: consensus summary statement.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(10 Suppl):129s-132s.
-
2003: Markman Maurie
Intraperitoneal antineoplastic drug delivery: rationale and results.
The lancet oncology 2003;4(5):277-83.
-
2003: Rothenberg Mace L; Liu P Y; Braly Patricia S; Wilczynski Sharon P; Hannigan Edward V; Wadler Scott; Stuart Gavin; Jiang Caroline; Markman Maurie; Alberts David S
Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(7):1313-9.
-
2003: Markman Maurie
Rationale for maintenance or consolidation therapy in ovarian cancer.
Clinical advances in hematology & oncology : H&O 2003;1(3):176-8.
-
2003: Markman Maurie
Management of toxicities associated with the administration of taxanes.
Expert opinion on drug safety 2003;2(2):141-6.
-
2003: Markman Maurie; Glass Tracy; Smith Harriet O; Hatch Kenneth D; Weiss Geoffrey R; Taylor Sarah A; Goodwin J Wendall; Alberts David S
Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial.
Gynecologic oncology 2003;88(3):282-8.
-
2003: Markman Maurie
Managing taxane toxicities.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2003;11(3):144-7.
-
2003: Xu Yan; Xiao Yi-Jin; Zhu Kui; Baudhuin Linnea M; Lu Jun; Hong Guiying; Kim Kwan-Sik; Cristina Kelly L; Song Li; S Williams Freager; Elson Paul; Markman Maurie; Belinson Jerome
Unfolding the pathophysiological role of bioactive lysophospholipids.
Current drug targets. Immune, endocrine and metabolic disorders 2003;3(1):23-32.
-
2003: Markman Maurie
Is there a role for aggressive surgical cytoreduction in patients with known metastatic cancer?
Current oncology reports 2003;5(1):1-2.
-
2003: Markman Maurie
Supportive care.
Cancer chemotherapy and biological response modifiers 2003;21():709-16.
-
2002: Ozols Robert F; Markman Maurie; Thigpen J Tate
ICON3 and chemotherapy for ovarian cancer.
Lancet 2002;360(9350):2086-7; author reply 2088.
-
2002: Markman Maurie
Challenging ovarian cancer: how can we improve quantity and quality of life?
MedGenMed : Medscape general medicine 2002;4(4):10.
-
2002: Markman Maurie
Advertising genetic testing.
The Hastings Center report 2002;32(6):5.
-
2002: Alberts David S; Markman Maurie; Armstrong Deborah; Rothenberg Mace L; Muggia Franco; Howell Stephen B
Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):3944-6.
-
2002: Markman Maurie
Safety issues in using complementary and alternative medicine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(18 Suppl):39S-41S.
-
2002: Markman Maurie
The prophylactic administration of recombinant erythropoietin in the management of ovarian cancer: time for a definitive phase 3 randomized trial.
Gynecologic oncology 2002;86(3):237-8.
-
2002: Markman Maurie
Does palliative chemotherapy palliate?
Current oncology reports 2002;4(5):361.
-
2002: Markman Maurie
Progress in preventing chemotherapy-induced nausea and vomiting.
Cleveland Clinic journal of medicine 2002;69(8):609-10, 612, 615-7.
-
2002: Markman Maurie; Kulp Barbara; Peterson Gertrude; Kennedy Alexander; Belinson Jerome
Second-line therapy of ovarian cancer with Paclitaxel administered by both the intravenous and intraperitoneal routes: rationale and case reports.
Gynecologic oncology 2002;86(1):95-8.
-
2002: Markman Margaret R; Peterson Gertrude; Kulp Barbara; Markman Maurie
Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Gynecologic oncology 2002;85(3):435-7.
-
2002: Mekhail Tarek M; Markman Maurie
Paclitaxel in cancer therapy.
Expert opinion on pharmacotherapy 2002;3(6):755-66.
-
2002: Markman Maurie
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'?
Cleveland Clinic journal of medicine 2002;69(5):368-9, 375-6.
-
2002: Markman Maurie; Hall James; Spitz Daniel; Weiner Sheldon; Carson Linda; Van Le Linda; Baker Mark
Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(9):2365-9.
-
2002: Markman Maurie
The use of PET scanning in ovarian cancer.
Gynecologic oncology 2002;85(2):391; author reply 391-2.
-
2002: Bloss Jeffrey D; Blessing John A; Behrens Brent C; Mannel Robert S; Rader Janet S; Sood Anil K; Markman Maurie; Benda Jo
Randomized trial of cisplatin and ifosfamide with or without bleomycin in squamous carcinoma of the cervix: a gynecologic oncology group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1832-7.
-
2002: Markman Maurie
Role of chemotherapy in the management of ovarian cancer.
Expert review of anticancer therapy 2002;2(1):90-6.
-
2002: Markman Maurie
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Seminars in oncology 2002;29(1 Suppl 1):9-10.
-
2002: Barakat Richard R; Sabbatini Paul; Bhaskaran Dharmendra; Revzin Margarita; Smith Alex; Venkatraman Ennapadam; Aghajanian Carol; Hensley Martee; Soignet Steven; Brown Carol; Soslow Robert; Markman Maurie; Hoskins William J; Spriggs David
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):694-8.
-
2002: Markman Maurie
Hypersensitivity reactions to carboplatin.
Gynecologic oncology 2002;84(2):353-4.
-
2002: Mekhail Tarek M; Markman Maurie
Acanthosis nigricans with endometrial carcinoma: case report and review of the literature.
Gynecologic oncology 2002;84(2):332-4.
-
2002: Markman Maurie
Supportive care.
Cancer chemotherapy and biological response modifiers 2002;20():627-32.
-
2001: Markman M; Kennedy A; Kim J
Potential clinical utility of CA-125 in responsive but persistent large-volume ovarian cancer following platinum-based chemotherapy.
Gynecologic oncology 2001;83(3):593-5.
-
2001: Smith S A; Richards W E; Caito K; Hanjani P; Markman M; DeGeest K; Gallion H H
BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study.
Gynecologic oncology 2001;83(3):586-92.
-
2001: Markman M
Interactions between academic oncology and alternative/complementary/integrative medicine: complex but necessary.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(18 Suppl):52S-53S.
-
2001: Zanotti K M; Rybicki L A; Kennedy A W; Belinson J L; Webster K D; Kulp B; Peterson G; Markman M
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):3126-9.
-
2001: Markman M
Prolonged symptom-free survival in a patient with persistent primary peritoneal carcinoma and a rising CA-125: a note of caution.
Gynecologic oncology 2001;81(3):509-11.
-
2001: Markman M
Intraperitoneal chemotherapy is appropriate first line therapy for patients with optimally debulked ovarian cancer.
Critical reviews in oncology/hematology 2001;38(3):171-5.
-
2001: Rohl J; Kushner D; Markman M
Chronic administration of single-agent paclitaxel in gynecologic malignancies.
Gynecologic oncology 2001;81(2):201-5.
-
2001: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):1901-5.
-
2001: Markman M; Bundy B N; Alberts D S; Fowler J M; Clark-Pearson D L; Carson L F; Wadler S; Sickel J
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1001-7.
-
2001: Markman M
Is there a role for intraperitoneal chemotherapy in the management of ovarian cancer?
Oncology (Williston Park, N.Y.) 2001;15(1):93-8; discussion 103-5.
-
2001: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
Journal of cancer research and clinical oncology 2001;127(1):55-8.
-
2001: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 2001;19():691-9.
-
2001: Zanotti K M; Markman M
Prevention and management of antineoplastic-induced hypersensitivity reactions.
Drug safety : an international journal of medical toxicology and drug experience 2001;24(10):767-79.
-
2001: Markman M
Intraperitoneal drug delivery of antineoplastics.
Drugs 2001;61(8):1057-65.
-
2000: Markman M
Treatment of ovarian cancers not of epithelial origin.
Cleveland Clinic journal of medicine 2000;67(11):839-42.
-
2000: Zanotti K M; Belinson J L; Kennedy A W; Webster K D; Markman M
Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
Gynecologic oncology 2000;79(2):211-5.
-
2000: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Gynecologic oncology 2000;79(1):116-9.
-
2000: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Gynecologic oncology 2000;78(3 Pt 1):369-72.
-
2000: Markman M
Limits to the "benefits" from our oncologic interventions: a case report.
Gynecologic oncology 2000;78(2):261-2.
-
2000: Kushner D M; Webster K D; Belinson J L; Rybicki L A; Kennedy A W; Markman M
Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Gynecologic oncology 2000;78(2):221-7.
-
2000: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Gynecologic oncology 2000;78(1):43-6.
-
2000: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia.
Journal of cancer research and clinical oncology 2000;126(5):298-300.
-
2000: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Declining CA-125 in an ovarian cancer patient with progression of measurable disease: a rational hypothesis for discordant results.
Gynecologic oncology 2000;77(2):321-2.
-
2000: Markman M
The genetics, screening, and treatment of epithelial ovarian cancer: an update.
Cleveland Clinic journal of medicine 2000;67(4):294-8.
-
2000: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):102-5.
-
2000: Markman M; Bookman M A
Second-line treatment of ovarian cancer.
The oncologist 2000;5(1):26-35.
-
1999: Markman M; Blessing J A; DeGeest K; Morgan M; Look K Y; Herzog T J; Rose P G
Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Gynecologic oncology 1999;75(3):444-6.
-
1999: Abramovich D; Markman M; Kennedy A; Webster K; Belinson J
Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma.
Journal of cancer research and clinical oncology 1999;125(12):697-8.
-
1999: Berek J S; Markman M; Stonebraker B; Lentz S S; Adelson M D; DeGeest K; Moore D
Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study.
Gynecologic oncology 1999;75(1):10-4.
-
1999: Markman M
Intraperitoneal chemotherapy.
Critical reviews in oncology/hematology 1999;31(3):239-46.
-
1999: Zanotti K M; Belinson J L; Kennedy A W; Webster K D; Markman M
The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma.
Gynecologic oncology 1999;74(2):272-7.
-
1999: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Journal of cancer research and clinical oncology 1999;125(7):427-9.
-
1999: Berek J S; Markman M; Blessing J A; Kucera P R; Nelson B E; Anderson B; Hanjani P
Intraperitoneal alpha-interferon alternating with cisplatin in residual ovarian carcinoma: a phase II Gynecologic Oncology Group study.
Gynecologic oncology 1999;74(1):48-52.
-
1999: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Persistent chemosensitivity to platinum and/or paclitaxel in metastatic endometrial cancer.
Gynecologic oncology 1999;73(3):422-3.
-
1999: Husain A; Sabbatini P; Spriggs D; Fennelly D; Aghajanian C; Barakat R; Curtin J; Venkatraman E; Hoskins W; Markman M
Phase II trial of intraperitoneal cisplatin and mitoxantrone in patients with persistent ovarian cancer.
Gynecologic oncology 1999;73(1):96-101.
-
1999: Markman M
Diagnosis and management of superior vena cava syndrome.
Cleveland Clinic journal of medicine 1999;66(1):59-61.
-
1999: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias.
Gynecologic oncology 1999;72(1):100-1.
-
1999: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 1999;18():590-600.
-
1998: Kennedy A W; Markman M; Webster K D; Kulp B; Peterson G; Rybicki L A; Belinson J L
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Gynecologic oncology 1998;71(2):288-90.
-
1998: Markman M
Why should cancer patients participate in clinical trials?
Cleveland Clinic journal of medicine 1998;65(9):497-9.
-
1998: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 1998;71(1):113-5.
-
1998: Markman M; Kennedy A; Sutton G; Hurteau J; Webster K; Peterson G; Kulp B; Belinson J
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Gynecologic oncology 1998;70(2):272-4.
-
1998: Xu Y; Shen Z; Wiper D W; Wu M; Morton R E; Elson P; Kennedy A W; Belinson J; Markman M; Casey G
Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.
JAMA : the journal of the American Medical Association 1998;280(8):719-23.
-
1998: Markman M; Brady M F; Spirtos N M; Hanjani P; Rubin S C
Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2620-4.
-
1998: Markman M; Blessing J A; Moore D; Ball H; Lentz S S
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
Gynecologic oncology 1998;69(3):226-9.
-
1998: Markman M
Intraperitoneal therapy of ovarian cancer.
Seminars in oncology 1998;25(3):356-60.
-
1998: Markman M; Rose P G; Jones E; Horowitz I R; Kennedy A; Webster K; Belinson J; Fusco N; Fluellen L; Kulp B; Peterson G; McGuire W P
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1849-51.
-
1998: Markman M
The high cost of terminal care: balancing conflicting goals.
Cleveland Clinic journal of medicine 1998;65(4):219-21.
-
1998: Markman M
Cancer and the mind: separating fact from fiction.
Cleveland Clinic journal of medicine 1998;65(2):107-9.
-
1998: Markman M
Thirty-ninth annual meeting of the American Society of Hematology. 5-9 December 1997, San Diego.
Journal of cancer research and clinical oncology 1998;124(7):407-8.
-
1998: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.
Journal of cancer research and clinical oncology 1998;124(6):326-8.
-
1997: Shapiro F; Schneider J; Markman M; Reichman B S; Venkatraman E; Barakat R; Almadrones L; Spriggs D
High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Gynecologic oncology 1997;67(1):39-45.
-
1997: Markman M
Assessing and minimizing reproductive risks of cancer chemotherapy.
Cleveland Clinic journal of medicine 1997;64(9):465-7.
-
1997: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum-based regimens.
Gynecologic oncology 1997;65(3):434-6.
-
1997: Markman M
Ethical issues in clinical trials in oncology.
Cleveland Clinic journal of medicine 1997;64(5):275-7.
-
1997: Markman M
Calculating cancer risk: it is harder than it seems.
Cleveland Clinic journal of medicine 1997;64(4):220-1.
-
1997: Markman M; Peereboom D M
From serendipity to design: the evolution of drug development in oncology.
Cleveland Clinic journal of medicine 1997;64(3):155-63.
-
1997: Markman M
Topotecan: an important new drug in the management of ovarian cancer.
Seminars in oncology 1997;24(1 Suppl 5):S5-1.
-
1997: Markman M
The dilemma of evaluating and treating cancer of unknown primary site.
Cleveland Clinic journal of medicine 1997;64(2):73-5.
-
1997: Markman M
When and how to use serum tumor markers in clinical practice.
Cleveland Clinic journal of medicine 1997;64(1):27-9.
-
1997: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 1997;17():672-83.
-
1997: Markman M
Thirty-eighth Annual Meeting of the American Society of Hematology.
Journal of cancer research and clinical oncology 1997;123(4):235-6.
-
1997: Markman M; Kennedy A; Webster K; Peterson G; Kulp B; Belinson J
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.
Journal of cancer research and clinical oncology 1997;123(4):224-6.
-
1996: Connelly E; Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
Gynecologic oncology 1996;62(2):166-8.
-
1996: Markman M; Iseminger K A; Hatch K D; Creasman W T; Barnes W; Dubeshter B
Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report.
Gynecologic oncology 1996;62(1):4-6.
-
1996: Markman M; Homesley H; Norberts D A; Schink J; Abbas F; Miller A; Soper J; Teng N; Hammond N; Muggia F; Israel M; Sweatman T
Phase 1 trial of intraperitoneal AD-32 in gynecologic malignancies.
Gynecologic oncology 1996;61(1):90-3.
-
1996: Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.
Gynecologic oncology 1996;60(3):435-7.
-
1996: Markman M; Hakes T; Barakat R; Curtin J; Almadrones L; Hoskins W
Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):796-9.
-
1996: Markman M
Eighty-seventh annual meeting of the American Association for Cancer Research. Washington, D,C., 20-24 April 1996.
Journal of cancer research and clinical oncology 1996;122(9):568-9.
-
1996: Markman M
Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies?
Cancer investigation 1996;14(5):498-500.
-
1996: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 1996;16():644-54.
-
1995: Francis P; Rowinsky E; Schneider J; Hakes T; Hoskins W; Markman M
Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(12):2961-7.
-
1995: Markman M
Intraperitoneal paclitaxel in the management of ovarian cancer.
Seminars in oncology 1995;22(5 Suppl 12):86-7.
-
1995: Markman M
Rationale for examining the combination of paclitaxel and ifosfamide in the treatment of advanced ovarian cancer.
Seminars in oncology 1995;22(3 Suppl 6):88-9.
-
1995: Markman M; Francis P; Rowinsky E; Hoskins W
Intraperitoneal paclitaxel: a possible role in the management of ovarian cancer?
Seminars in oncology 1995;22(3 Suppl 6):84-7.
-
1995: Markman M
Surgery for support and palliation in patients with malignant disease.
Seminars in oncology 1995;22(2 Suppl 3):91-4.
-
1995: Markman M
The use of chemotherapy as palliative treatment for patients with advanced ovarian cancer.
Seminars in oncology 1995;22(2 Suppl 3):25-9.
-
1995: Markman M
26th annual meeting of the Society of Gynecologic Oncologists. San Francisco, 18-22 February 1995.
Journal of cancer research and clinical oncology 1995;121(5):315-6.
-
1995: Markman M
36th annual meeting of the American Society of Hematology. Nashville, 2-6 December 1994.
Journal of cancer research and clinical oncology 1995;121(5):313-4.
-
1995: Markman M
The objective clinical scientist versus the advocate: a complex ethical and political dilemma facing cancer investigators and the public.
Cancer investigation 1995;13(3):324-6.
-
1995: Markman M
Thirty-first annual meeting of the American Society of Clinical Oncology. Los Angeles, California, 20-23 May 1995.
Journal of cancer research and clinical oncology 1995;121(8):490-1.
-
1995: Markman M
86th annual meeting of the American Association for Cancer Research. Toronto, Canada, March 18-22, 1995.
Journal of cancer research and clinical oncology 1995;121(7):439-40.
-
1995: Markman M
Is there a role for intraperitoneal therapy in the management of gastrointestinal malignancies?
Cancer investigation 1995;13(6):625-8.
-
1994: Markman M
Follow-up of the asymptomatic patient with ovarian cancer.
Gynecologic oncology 1994;55(3 Pt 2):S134-7.
-
1994: Markman M
Realistic goals of cancer therapy: effective and humane care.
Cleveland Clinic journal of medicine 1994;61(6):468-72.
-
1994: Markman M
Introduction: treatment of malignancies poorly responsive to currently available antineoplastic therapy.
Seminars in oncology 1994;21(4 Suppl 7):1-2.
-
1994: Rusch V; Saltz L; Venkatraman E; Ginsberg R; McCormack P; Burt M; Markman M; Kelsen D
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(6):1156-63.
-
1994: Markman M
Intraperitoneal cisplatin and carboplatin in the management of ovarian cancer.
Seminars in oncology 1994;21(2 Suppl 2):17-9; quiz 20, 58.
-
1994: Markman M
Common complications and emergencies associated with cancer and its therapy.
Cleveland Clinic journal of medicine 1994;61(2):105-14; quiz 162.
-
1994: Markman M
Ovarian cancer update: management challenges and advances.
Cleveland Clinic journal of medicine 1994;61(1):51-8; quiz 80-2.
-
1994: Markman M
Fourth biennial meeting of the International Gynecologic Cancer Society, Stockholm 1993.
Journal of cancer research and clinical oncology 1994;120(4):248-9.
-
1994: Markman M
Thirty-fifth annual meeting of the American Society of Hematology, St. Louis, Missouri, December 1993.
Journal of cancer research and clinical oncology 1994;120(7):437-8.
-
1994: Markman M
Twenty-fifth meeting of the Society of Gynecologic Oncologists. Orlando, Florida, February 1994.
Journal of cancer research and clinical oncology 1994;120(9):562-3.
-
1994: Markman M
When regulatory requirements conflict with ethical study design: the case of oral ondansetron.
Cancer investigation 1994;12(6):654-6.
-
1994: Markman M; Francis P; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis J L; Rubin S; Curtin J; Barakat R
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5 Suppl 6():S55-8.
-
1994: Markman M
30th annual meeting of the American Society of Clinical Oncology. Dallas, Texas, May 1994.
Journal of cancer research and clinical oncology 1994;120(12):745-6.
-
1994: Markman M
85th annual meeting of the American Association for Cancer Research. San Francisco, California, April 1994.
Journal of cancer research and clinical oncology 1994;120(12):743-4.
-
1994: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 1994;15():665-74.
-
1993: Markman M
Salvage therapy in ovarian cancer: is there a role for intraperitoneal drug delivery?
Gynecologic oncology 1993;51(1):86-9.
-
1993: Markman M; Blessing J A; Major F; Manetta A
Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study.
Gynecologic oncology 1993;50(2):191-5.
-
1993: Reichman B; Markman M; Hakes T; Rubin S; Jones W; Curtin J; Barakat R; Almadrones L; Lewis J L; Hoskins W
Mitomycin-C plus a 3-day continuous intravenous infusion of 5-fluorouracil: an inactive salvage regimen for platinum-resistant ovarian carcinoma.
Gynecologic oncology 1993;50(1):30-3.
-
1993: Markman M; Reichman B; Hakes T; Rubin S; Lewis J L; Jones W; Barakat R; Curtin J; Almadrones L; Hoskins W
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer.
Gynecologic oncology 1993;50(1):100-4.
-
1993: Markman M
Surgeon's skill key to ovarian cancer management.
Cleveland Clinic journal of medicine 1993;60(3):183-4.
-
1993: Markman M; Lewis J L; Saigo P; Hakes T; Rubin S; Jones W; Reichman B; Curtin J; Barakat R; Almadrones L
Impact of age on survival of patients with ovarian cancer.
Gynecologic oncology 1993;49(2):236-9.
-
1993: Markman M; Hakes T; Reichman B; Rubin S; Curtin J; Barakat R; Jones W; Lewis J L; Almadrones L; Hoskins W
Salvage intraperitoneal mitoxantrone therapy of ovarian cancer: influence of increasing the volume of treatment.
Gynecologic oncology 1993;49(2):185-9.
-
1993: Markman M; Reichman B; Hakes T; Rubin S; Jones W; Lewis J L; Barakat R; Curtin J; Almadrones L; Hoskins W
The use of recombinant human erythropoietin to prevent carboplatin-induced anemia.
Gynecologic oncology 1993;49(2):172-6.
-
1993: Markman M; Alberts D; Rubin S; Hakes T; Lewis J L; Reichman B; Jones W; Curtin J; Barakat R; Brodar F
Evidence for persistence of mitoxantrone within the peritoneal cavity following intraperitoneal delivery.
Gynecologic oncology 1993;48(2):185-8.
-
1993: Markman M
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity.
Critical reviews in oncology/hematology 1993;14(1):15-28.
-
1993: Markman M
Report from the 28th Annual Meeting of the American Society of Clinical Oncology. 17-19 May 1992.
Journal of cancer research and clinical oncology 1993;119(6):369-70.
-
1993: Markman M; DeMarco L C; Birkhofer M; Budman D; Hakes T; Reichman B; Rubin S; Jones W; Barakat R; Curtin J
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapy.
Journal of cancer research and clinical oncology 1993;119(4):234-6.
-
1993: Markman M
Report from the 24th annual meeting of the Society of Gynecologic Oncologists, February 7-10, 1993.
Journal of cancer research and clinical oncology 1993;119(12):759-60.
-
1993: Francis P; Markman M; Hakes T; Reichman B; Rubin S; Jones W; Lewis J L; Curtin J; Barakat R; Phillips M
Diethyldithiocarbamate chemoprotection of carboplatin--induced hematological toxicity.
Journal of cancer research and clinical oncology 1993;119(6):360-2.
-
1993: Markman M
Report from the 34th annual meeting of the American Society of Hematology, December 4-8, 1992.
Journal of cancer research and clinical oncology 1993;119(11):695-6.
-
1993: Markman M
Salvage intraperitoneal chemotherapy for ovarian cancer: a possible role for mitoxantrone?
European journal of cancer (Oxford, England : 1990) 1993;29A(9):1225-6.
-
1993: Markman M
Supportive care.
Cancer chemotherapy and biological response modifiers 1993;14():641-50.
-
1993: Markman M
Report from the 29th annual meeting of the American Society of Clinical Oncology, 16-18 May 1993, Orlando, Florida.
Journal of cancer research and clinical oncology 1993;120(1-2):119-20.
-
1993: Markman M
Report from the Second National Cancer Institute Workshop on Taxol and Taxus. 23-24 September 1992.
Journal of cancer research and clinical oncology 1993;119(7):439-40.
-
1992: Markman M; Hakes T; Reichman B; Barakat R; Curtin J; Jones W; Lewis J L; Rubin S; Almadrones L; Hoskins W
Exploring the use of chronic low-dose oral etoposide in ovarian cancer: is there a role for this "new drug" in the management of platinum-refractory disease?
Seminars in oncology 1992;19(6 Suppl 14):25-7.
-
1992: Markman M; Reichman B; Hakes T; Rubin S; Jones W; Lewis J L; Barakat R; Curtin J; Almadrones L; Hoskins W
Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer.
Gynecologic oncology 1992;47(3):353-7.
-
1992: Markman M
Systemic therapy for gynecologic cancer.
Current opinion in oncology 1992;4(5):939-45.
-
1992: Barakat R R; Rubin S C; Wong G; Saigo P E; Markman M; Hoskins W J
Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases.
Obstetrics and gynecology 1992;80(4):660-4.
-
1992: Markman M; Reichman B; Hakes T; Lewis J L; Jones W; Rubin S; Barakat R; Curtin J; Almadrones L; Hoskins W
Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1479-84.
-
1992: Markman M; Rowinsky E; Hakes T; Reichman B; Jones W; Lewis J L; Rubin S; Curtin J; Barakat R; Phillips M
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(9):1485-91.
-
1992: Hakes T B; Chalas E; Hoskins W J; Jones W B; Markman M; Rubin S C; Chapman D; Almadrones L; Lewis J L
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma.
Gynecologic oncology 1992;45(3):284-9.
-
1992: Rusch V W; Niedzwiecki D; Tao Y; Menendez-Botet C; Dnistrian A; Kelsen D; Saltz L; Markman M
Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(6):1001-6.
-
1992: Markman M; Berek J S; Blessing J A; McGuire W P; Bell J; Homesley H D
Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: lessons learned from a Gynecologic Oncology Group phase II trial of ip cisplatin and recombinant alpha-interferon.
Gynecologic oncology 1992;45(1):3-8.
-
1992: Markman M; Hakes T; Reichman B; Lewis J L; Rubin S; Jones W; Almadrones L; Pizzuto F; Hoskins W
Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(2):243-8.
-
1992: Markman M; Jones W; Lewis J L; Rubin S; Hakes T; Reichman B; Barakat R; Curtin J; Almadrones L; Hoskins W
Impact of laparotomy finding of significant intraabdominal adhesions on the surgically defined complete response rate to subsequent salvage intraperitoneal chemotherapy.
Journal of cancer research and clinical oncology 1992;118(2):163-5.
-
1992: Markman M; Kelsen D
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma.
Journal of cancer research and clinical oncology 1992;118(7):547-50.
-
1992: Markman M; Reichman B; Hakes T; Curtin J; Barakat R; Rubin S; Jones W; Lewis J L; Almadrones L; Hoskins W
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy.
Journal of cancer research and clinical oncology 1992;118(5):391-4.
-
1992: Markman M; Reichman B; Hakes T; Barakat R; Curtin J; Rubin S; Jones W; Lewis J L; Almadrones L; Hoskins W
Salvage intraperitoneal therapy of small-volume residual ovarian cancer: impact of pretreatment finding of peritoneal carcinomatosis on the surgical complete response rate.
Journal of cancer research and clinical oncology 1992;118(3):235-7.
-
1992: Markman M; Hakes T; Reichman B; Curtin J; Barakat R; Rubin S; Jones W; Lewis J L; Almadrones L; Hoskins W
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.
Journal of cancer research and clinical oncology 1992;119(1):55-7.
-
1992: Markman M
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncology.
The Journal of clinical ethics 1992;3(3):193-5.
-
1991: Reichman B; Markman M; Hakes T; Budnick A; Rubin S; Jones W; Almadrones L; Lewis J L; Hoskins W
Phase II trial of high-dose cisplatin with sodium thiosulfate nephroprotection in patients with advanced carcinoma of the uterine cervix previously untreated with chemotherapy.
Gynecologic oncology 1991;43(2):159-63.
-
1991: Markman M
Taxol: an important new drug in the management of epithelial ovarian cancer.
The Yale journal of biology and medicine 1991;64(6):583-90.
-
1991: Markman M; Reichman B; Hakes T; Jones W; Lewis J L; Rubin S; Almadrones L; Hoskins W
Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(10):1801-5.
-
1991: Barakat R R; Rubin S C; Saigo P E; Chapman D; Lewis J L; Jones W B; Hakes T B; Markman M; Reichman B; Hoskins W J
Cisplatin-based combination chemotherapy in carcinoma of the fallopian tube.
Gynecologic oncology 1991;42(2):156-60.
-
1991: Rubin S C; Hoskins W J; Saigo P E; Chapman D; Hakes T B; Markman M; Reichman B; Almadrones L; Lewis J L
Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy.
Gynecologic oncology 1991;42(2):137-41.
-
1991: Markman M
Intraperitoneal chemotherapy.
Seminars in oncology 1991;18(3):248-54.
-
1991: Markman M; Hakes T; Reichman B; Lewis J L; Rubin S; Jones W; Almadrones L; Hoskins W
Phase II trial of weekly or biweekly intraperitoneal mitoxantrone in epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(6):978-82.
-
1991: Markman M; Rothman R; Hakes T; Reichman B; Lewis J L; Rubin S; Jones W; Almadrones L; Hoskins W
Late effects of cisplatin-based chemotherapy on renal function in patients with ovarian carcinoma.
Gynecologic oncology 1991;41(3):217-9.
-
1991: Davidson S A; Rubin S C; Markman M; Jones W B; Hakes T B; Reichman B; Almadrones L; Chapman D; Lewis J L; Hoskins W J
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system.
Gynecologic oncology 1991;41(2):101-6.
-
1991: Smith-Rogers J A; Tong W P; Duafala M E; Markman M; Bertino J R
High-performance liquid chromatographic method for the simultaneous measurement of floxuridine and fluorouracil in human body fluids.
Journal of chromatography 1991;566(1):147-54.
-
1991: Markman M; Rothman R; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Lewis J L
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(3):389-93.
-
1991: Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Yordan E L; Eriksson J; Lewis J L
Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1991;9(2):204-10.
-
1991: Curtin J P; Hoskins W J; Rubin S C; Jones W B; Hakes T B; Markman M M; Reichman B; Almadrones L; Lewis J L
Chemotherapy-induced neutropenia and fever in patients receiving cisplatin-based chemotherapy for ovarian malignancy.
Gynecologic oncology 1991;40(1):17-20.
-
1991: Markman M; D'Acquisto R; Iannotti N; Kris M; Hakes T; Bajorin D; Bosl G; Reichman B; Casper E; Magill G
Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate.
Journal of cancer research and clinical oncology 1991;117(2):151-5.
-
1990: Ng L W; Rubin S C; Hoskins W J; Jones W B; Hakes T B; Markman M; Reichman B; Almadrones L; Lewis J L
Aggressive chemosurgical debulking in patients with advanced ovarian cancer.
Gynecologic oncology 1990;38(3):358-63.
-
1990: Rubin S C; Finstad C L; Hoskins W J; Saigo P E; Provencher D M; Federici M G; Hakes T B; Markman M; Reichman B S; Lloyd K O
Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
American journal of obstetrics and gynecology 1990;163(1 Pt 1):69-73.
-
1990: Markman M; George M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadrones L; Lewis J L
Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(1):146-50.
-
1989: Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P
Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(9):1327-32.
-
1989: Hoskins W J; Rubin S C; Dulaney E; Chapman D; Almadrones L; Saigo P; Markman M; Hakes T; Reichman B; Jones W B
Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.
Gynecologic oncology 1989;34(3):365-71.
-
1989: Rubin S C; Hoskins W J; Markman M; Federici M; Lloyd K O; Lewis J L
Synergistic activity of tumor necrosis factor and interferon in a nude mouse model of human ovarian cancer.
Gynecologic oncology 1989;34(3):353-6.
-
1989: Markman M
Intraperitoneal cisplatin chemotherapy in the management of ovarian carcinoma.
Seminars in oncology 1989;16(4 Suppl 6):79-82.
-
1989: Markman M; Hakes T; Reichman B; Hoskins W; Rubin S; Jones W; Almadones L; Lewis J L
Intraperitoneal therapy in the management of ovarian carcinoma.
The Yale journal of biology and medicine 1989;62(4):393-403.
-
1989: Smith J A; Morris A; Duafala M E; Bertino J R; Markman M; Kleinberg M
Stability of floxuridine and leucovorin calcium admixtures for intraperitoneal administration.
American journal of hospital pharmacy 1989;46(5):985-9.
-
1989: Rubin S C; Hoskins W J; Markman M; Hakes T; Lewis J L
Long-term access to the peritoneal cavity in ovarian cancer patients.
Gynecologic oncology 1989;33(1):46-8.
-
1989: Rubin S C; Hoskins W J; Hakes T B; Markman M; Reichman B S; Chapman D; Lewis J L
Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer.
American journal of obstetrics and gynecology 1989;160(3):667-71.
-
1989: Markman M; Reichman B; Hakes T; Hoskins W; Rubin S; Jones W; Lewis J L
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Acta medica Austriaca 1989;16(3-4):65-7.
-
1989: Markman M
Issues involved in providing quality and optimal care for the cancer patient in the era of cost containment.
Cancer investigation 1989;7(4):395-8.
-
1988: Rubin S C; Hoskins W J; Hakes T B; Markman M; Cain J M; Lewis J L
Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors.
American journal of obstetrics and gynecology 1988;159(5):1094-8.
-
1988: Rubin S C; Dulaney E D; Markman M; Hoskins W J; Saigo P E; Lewis J L
Peritoneal cytology as an indicator of disease in patients with residual ovarian carcinoma.
Obstetrics and gynecology 1988;71(6 Pt 1):851-3.
-
1988: Markman M
An argument in support of cost-effectiveness analysis in oncology.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(6):937-9.
-
1988: D'Acquisto R; Markman M; Hakes T; Rubin S; Hoskins W; Lewis J L
A phase I trial of intraperitoneal recombinant gamma-interferon in advanced ovarian carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(4):689-95.
-
1988: Reichman B; Markman M; Hakes T; Kemeny N; Kelsen D; Hoskins W; Rubin S; Lewis J L
Phase I trial of concurrent intraperitoneal and continuous intravenous infusion of fluorouracil in patients with refractory cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1988;6(1):158-62.
-
1987: Markman M
Intraperitoneal chemotherapy as treatment of ovarian carcinoma: why, how, and when?
Obstetrical & gynecological survey 1987;42(9):533-9.
-
1987: Markman M
Current status of intracavitary chemotherapy.
Oncology (Williston Park, N.Y.) 1987;1(1):25-30.
-
1987: Markman M
Intraperitoneal chemotherapy for ovarian carcinoma.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1987;41(8):420-4.
-
1987: Markman M
Clinical cancer research, DNR orders, and medical economics: a complex interrelationship.
Cancer investigation 1987;5(3):237-9.
Sign-in to see more